RELMADA THERAPEUTICS, INC. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2026-03-31 was -$65.65K.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2024-09-30 was -$89.60K.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2024-03-31 was -$25.00B.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2022-09-30 was -$50.00K.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for fiscal 2023 was -$98.46K, a 100.23% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for fiscal 2022 was $42.73M, a 73.50% decline from fiscal 2021.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for fiscal 2021 was $161.23M.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, other for fiscal 2019 was $17.76M.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2026-03-31 | -$65.65K 10-Q · filed 2026-05-12 | |
| 2024-09-30 | -$89.60K 10-Q · filed 2024-11-07 | |
| 2024-03-31 | -$25.00B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | -$98.46K 10-K · filed 2024-03-19 | |
| 2022-12-31 | $42.73M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$50.00K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $29.58M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $161.23M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$42.01K 10-Q · filed 2022-11-10 | |
| 2020-06-30 | $19.86M 10-Q · filed 2021-11-12 | |
| 2019-06-30 | $10.86M 10-Q · filed 2020-11-12 | $17.76M 10-K · filed 2021-03-24 |
| 2019-03-31 | $1.73M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $5.18M 10-Q · filed 2019-05-15 | |
| 2007-12-31 | $1.82M 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |